Full text

Turn on search term navigation

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Chronic stress significantly contributes to the development of depressive disorders, with the hypothalamic–pituitary–adrenal (HPA) axis playing a central role in mediating stress responses. This review examines the neurobiological alterations in the hippocampus linked to HPA axis dysregulation in chronic stress-associated depressive disorders. The prolonged activation of the HPA axis disrupts cortisol regulation, leading to the decline of both physical and mental health. The chronic stress-induced HPA axis dysfunction interacts with inflammatory pathways and generates oxidative stress, contributing to cellular damage and neuroinflammation that further aggravates depressive symptoms. These processes result in structural and functional alterations in the hippocampus, which is essential for emotional regulation and cognitive function. Comprehending the impact of chronic stress on the HPA axis and associated neurobiological pathways is essential for formulating effective interventions for depressive disorders. This review summarises the existing findings and underscores the necessity for future investigations into intervention strategies to improve physical and psychological wellbeing targeting at HPA axis dysregulation for the betterment of psychological wellbeing and human health.

Details

Title
Chronic Stress-Associated Depressive Disorders: The Impact of HPA Axis Dysregulation and Neuroinflammation on the Hippocampus—A Mini Review
Author
Ai Ai Lei 1 ; Vanessa Wen Xian Phang 1 ; Yu Zhao Lee 2 ; Audrey Siew Foong Kow 1   VIAFID ORCID Logo  ; Tham, Chau Ling 3   VIAFID ORCID Logo  ; Yu-Cheng, Ho 4 ; Lee, Ming Tatt 5   VIAFID ORCID Logo 

 Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia 
 Faculty of Medicine and Health Sciences, UCSI University, Kuala Lumpur 56000, Malaysia 
 Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia; Natural Medicine and Product Research Laboratory (NaturMeds), Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia 
 School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan 
 Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia; Office of Postgraduate Studies, UCSI University, Kuala Lumpur 56000, Malaysia 
First page
2940
Publication year
2025
Publication date
2025
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3188863250
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.